Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust ...

Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent ...

Vir Biotechnology has a cash runway into 2028 and pivotal 2026 catalysts for its lead hepatitis drugs. Learn why VIR stock is ...

Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...

From the early days of the Manhattan Project to the race to develop artificial intelligence, America has long recognized that being at the forefront of emerging technologies is critical to our ...

Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on VIR. Vir Biotechnology, ...

PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck ...

Launched with NSF funding this year, Penn’s AIRFoundry boasts the potential to radically speed up drug development.

Sana Biotechnology (SANA) is back in focus after Mayo Clinic agreed to collaborate on SC451 for type 1 diabetes and invest up to US$50 million, linking clinical expertise with fresh capital support.

"We anticipate dosing the first patient in the combination dose expansion cohorts in both early-line MCRPC and metastatic hormone-sensitive prostate cancer over the coming months." (President, CEO & ...

Do you want to be at the forefront of the rapidly growing biotechnology field? Do you want to develop products derived from living organisms and biomolecules? Do you have a passion for biochemistry, ...